Alpha Teknova, Inc. (TKNO)
| Previous Close | 2.0100 |
| Open | 2.0500 |
| Bid | 1.4400 x 200 |
| Ask | 2.6800 x 200 |
| Day's Range | 2.0500 - 2.0500 |
| 52 Week Range | 1.6200 - 4.2700 |
| Volume | |
| Avg. Volume | 12,446 |
| Market Cap | 83.688M |
| Beta (5Y Monthly) | 0.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
Insider MonkeyAlpha Teknova, Inc. (NASDAQ:TKNO) Q4 2023 Earnings Call Transcript
Alpha Teknova, Inc. (NASDAQ:TKNO) Q4 2023 Earnings Call Transcript March 12, 2024 Alpha Teknova, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and thank you for standing by. Welcome to Teknova Fourth Quarter 2023 Financial Results Conference Call. […]
- GuruFocus.com
Alpha Teknova Inc (TKNO) Faces Revenue Decline Amid Market Challenges
Full Year Revenue Drops by 11% as Company Implements Cost Reductions
GlobeNewswireTeknova Reports Fourth Quarter and Full Year 2023 Financial Results
Full year 2023 total revenue was $36.7 million, down 11% year-over-yearAchieved 36% annual growth in the number of Clinical Solutions customers in 2023Company provides 2024 revenue guidance of $35-38 million HOLLISTER, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financ
